The Patent Finder

Natco Pharma Limited

Also on record
Records under this name other than the patents Natco Pharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 34 patents it holds.

Back to Natco Pharma Limited

PatentTitleStatus Expires Confidence
US 8,735,415Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
Term ended
Term ended Oct 18, 2025 · From the USPTO record
Term endedTerm ended Oct 18, 2025From the USPTO record
US 8,183,253Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
Lapsed on the fee record
Ended May 22, 2024 · From the USPTO record
Lapsed on the fee recordEnded May 22, 2024From the USPTO record
US 9,227,948Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives
Lapsed on the fee record
Ended Jan 5, 2024 · From the USPTO record
Lapsed on the fee recordEnded Jan 5, 2024From the USPTO record
US 10,383,872Pharmaceutical compositions comprising phenylaminopyrimidine derivative
Lapsed on the fee record
Ended Aug 20, 2023 · From the USPTO record
Lapsed on the fee recordEnded Aug 20, 2023From the USPTO record
US 7,910,598Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
Lapsed on the fee record
Ended Mar 22, 2023 · From the USPTO record
Lapsed on the fee recordEnded Mar 22, 2023From the USPTO record
US 10,047,0881H-1,8-naphthyridin-2-ones as anti proliferative compounds
Lapsed on the fee record
Ended Aug 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Aug 14, 2022From the USPTO record
US 9,895,367Formulation comprising phenylaminopyrimidine derivative as active agent
Lapsed on the fee record
Ended Feb 20, 2022 · From the USPTO record
Lapsed on the fee recordEnded Feb 20, 2022From the USPTO record
US 9,765,0721H-1,8-naphthyridin-2ones as anti proliferative compounds
Lapsed on the fee record
Ended Sep 19, 2021 · From the USPTO record
Lapsed on the fee recordEnded Sep 19, 2021From the USPTO record
US 8,067,422Crystal form of phenylamino pyrimidine derivatives
Lapsed on the fee record
Ended Nov 29, 2019 · From the USPTO record
Lapsed on the fee recordEnded Nov 29, 2019From the USPTO record
US 7,960,545Process for the prepartion of erlotinib
Lapsed on the fee record
Ended Jun 14, 2019 · From the USPTO record
Lapsed on the fee recordEnded Jun 14, 2019From the USPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited